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PHARMACY
Pharmacy Help Desk Service
Farhat Zaheer-Specialist, Ambulatory Care Pharmacy
“A Customer centric approach to enhance patients’ safety and compliance 
through improved patient-pharmacist coordination.” 
Ambulatory care pharmacy practice is the 
provision of integrated, accessible health 
care services by pharmacists who are 
accountable for addressing medication needs 
and developing  sustained relationship with 
patients. This is accomplished through direct 
patient-pharmacist interaction, medication 
management, counseling and specialized 
services for ambulatory patients .The 
ambulatory care pharmacists are involved in 
direct care of a diverse patient population.
Researches have shown an increased risk of errors in ambulatory care 
including diagnostic and medication errors as the likelihood of an error 
is linked to a patient’s understanding of the indication, dosage schedule, 
proper administration, and potential adverse effects. Inability of patient to 
understand their medication schedule, side effects and possible interaction 
with other prescribed drug may compromise safety in short term and 
clinical outcomes in long term. Various factors like space constraint, 
insufficient counters and high volumes in ambulatory care pharmacies 
account for insufficient pharmacist-patient interactions, accessibility and 
timely responses for medication related queries.
In order to enhance patient-pharmacist interaction and to facilitate safe 
use of medications and patient’s compliance, pharmacy help desk was 
established at IBN-ZUHR front desk. It serves as an accessible and 
affordable way to address customer’s queries related to medication and 
their usage. It provides assistance to patients for:
	 l Drug availability, price
	 l Dosage, regime
	 l Directions for administration, precautions and drug interactions.
Patients are being facilitated through online email service, dedicated 
telephonic assistance, and qualified pharmacist services at help desk counter. 
Help desk services operates between 10 am till 2 pm, five days a week and 
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24/7 email service. Increased pharmacist-patient coordination not only enhances community’s awareness regarding 
medication usage but also serves as effective tool to minimize abrupt discontinuation of therapy and risk of self-
medication.
Pharmacy help desk has received an over-whelming response from customers since initiation of its services 
in June 2016 with over all 800 plus drug responses by pharmacist in the form of emails, telephonic calls and 
medication counseling services. More than 70 appreciations were received within one month. The services and 
coverage will be extended in phase-2 with more focus on specialized counseling services for specific disease 
and its medications like oncology and anti-coagulation counseling services. It will also initiate some value 
added service like refill reminders, advance booking for compounded medications to facilitate patients. 
 
New Guidelines for the Management of Aspergillosis
Kashif Hussain-Specialist, Infectious Disease 
Early diagnosis and treatment of the major forms of aspergillosis are the focus of a new practice guideline 
from the Infectious Diseases Society of America (IDSA). The evidence-based recommendations highlight data 
from clinical studies that evaluated new and current therapies for the management of Aspergillus infection, as 
well as data on the use of non-culture-based biomarkers for diagnosing infection. In particular, the guidelines 
focus on the management of the major forms of aspergillosis (allergic, chronic, and invasive), with special 
emphasis on invasive aspergillosis because it remains a significant cause of morbidity and mortality in high-
risk,immune-compromised patients.
It is emphasized that improved use of diagnostic tools has increased clinicians’ ability to make an early 
diagnosis of aspergillosis. Until molecular diagnostic techniques become more widely used in clinical 
laboratories, the guidelines recommend submission of tissue and fluid specimens for histopathologic, 
cytologic, and culture examination to diagnose invasive aspergillosis (IA). However, molecular techniques, 
such as DNA sequencing, should be used to identify Aspergillus species in cases that involve either isolates 
with atypical growth or concern for resistance.
If invasive pulmonary aspergillosis (IPA) is suspected in a patient, the guidelines recommend performing 
computed tomography scanning of the chest, regardless of chest radiography findings. Bronchoscopy with 
bronchoalveolar lavage is also recommended in these patients, unless significant comorbidities (such as 
bleeding or severe hypoxemia) preclude it. Detection of galactomannan (a component of the Aspergillus 
cell wall) in serum or bronchoalveolar lavage fluid is recommended as an accurate marker for the diagnosis 
of invasive aspergillosis in adults and children, when used in certain patient subpopulations, such as 
hematopoietic stem cell transplant recipients or patients with hematologic malignancies. The guidelines 
also discuss emerging diagnostic tools with the ability to further improve the early diagnosis of Aspergillus 
infection. For instance, Aspergillus polymerase chain reaction (PCR) testing has been shown to be more 
sensitive than culture in detecting the fungus in blood and respiratory fluids. Nevertheless, a promising 
diagnostic tool, these assays have not been standardized and validated for routine clinical use, and the role of 
PCR testing in patient management remains unclear. 
The availability of antifungal agents that are more active, better tolerated, and/or developed in extended-release 
formulations has also substantially improved therapy for patients at risk for serious Aspergillus infections.
If IPA is suspected, antifungal therapy should be initiated while diagnostic evaluation is ongoing. Voriconazole 
is recommended for primary treatment of IPA, although combination therapy with voriconazole and 
echinocandin may be warranted for some high-risk patients. Antifungal therapy for IPA should continue for at 
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least 6 to 12 weeks. Antifungal prophylaxis should also be instituted for patients with prolonged neutropenia 
who are at high risk for IA. Prophylactic regimens with posaconazole, voriconazole, and/or micafungin are 
considered to be most effective. The guidelines do not recommend routine testing for antifungal susceptibility. 
Instead, it should be reserved for cases in which infection with an azole-resistant isolate is suspected, or in 
which a patient is unresponsive to antifungal agents.
The guideline, which has also been endorsed by the Pediatric Infectious Diseases Society, recommends using 
the same antifungal agents for treatment of aspergillosis in children as are used in adults. However, dosing of 
many of these agents may be different for children. The authors also note that although voriconazole is only 
approved by the US Food and Drug Administration for children aged 12 years and older, it is the cornerstone 
of aspergillosis treatment in children of all ages. Yet, despite recent advances, the authors acknowledge that 
development of new antifungal agents is still needed for effective management of aspergillosis, because “even 
with optimal antifungal therapy the mortality rate remains high.”
Flu Vaccine
Ale Zehra , Clinical Pharmacist
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Overview of New CHEST Antithrombotic Guideline for Treatment of 
VTE (10th Edition)
Nida Najmi, Clinical Pharmacist, Ambulatory Care Pharmacy
American College of Chest Physicians (ACCP) issued new Antithrombotic Guidelines for the treatment of 
Venous Thromboembolism in January, 2016. This guideline provides most recent treatment options for VTE 
patients with updated recommendations on 12 topics that were in the 9th edition of these guidelines, and address 
3 new topics. Following are the 11 key points about this updated guideline:
l For VTE without an associated cancer diagnosis, all direct oral anticoagulants (dabigatran, rivaroxaban, 
 apixaban, or edoxaban) are recommended over vitamin K antagonist (VKA) therapy (all Grade 2B) and  
 VKA therapy is recommended over low molecular weight heparin (LMWH; Grade 2C).
l For VTE associated with cancer, LMWH is recommended over VKA (Grade 2B) or any direct oral 
 anticoagulants (all Grade  2C).
l Anticoagulants should stop after 3 months of therapy in patients with an acute, proximal deep venous  
 thrombosis (DVT) provoked by surgery rather than shorter or longer treatment courses (Grade 1B).
l Anticoagulants should also be stopped after 3 months in patients with a proximal DVT or pulmonary 
 embolism (PE) provoked by a nonsurgical transient risk factor over shorter or longer courses (Grade 1B for 
 high bleeding risk patients, Grade 2B for low or moderate bleeding risk patients).
l Anticoagulation should be given for 3 months in patients with a first unprovoked VTE and a high risk of 
 bleeding (Grade 1B), but should be extended without a scheduled stop date in patients with a low or moderate 
 risk of bleeding (Grade 2B).
l For patients with acute VTE who are treated with anticoagulation, the guideline recommends against the use 
 of an inferior vena cava filter (Grade 1B).
l For patients with an unprovoked proximal DVT or PE who are stopping anticoagulant therapy, the guideline 
 suggests the use of aspirin over no aspirin to prevent recurrent VTE if there are no contraindications to 
 aspirin therapy (Grade 2B).
l For patients with acute DVT, the guideline recommends against the use of compression stockings routinely 
 to prevent the post-thrombotic syndrome (Grade 2B).
l For patient with subsegmental PE and no DVT, the guideline suggests clinical surveillance over anticoagulation 
 when the risk of VTE recurrence is low (Grade 2C). The guideline recommends the use of anticoagulation 
 over surveillance when the risk of  VTE recurrence is high (Grade 2C).
l For patients with an acute PE and hypotension (massive PE), the guideline recommends the use of 
 thrombolytic therapy (Grade 2B), preferring systemic therapy over catheter-directed thrombolytic therapy  
 (Grade 2C).
l For patients with recurrent VTE while treated with a non-LMWH anticoagulant, the guideline recommends 
 changing to LMWH therapy (Grade 2C). If patients suffer a recurrent VTE while on LMWH treatment, the 
 guideline recommends increasing the LMWH dose (Grade 2C).
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From Pain Killer to Empathy Killer 
Nida Saleem, Trainee Pharmacist
A new study conducted by researchers at Ohio State University (Dominik Mischkowski, Jennifer Crocker, Baldwin 
M. Way, 2016) found that acetaminophen or paracetamol dulls a person to the trials and tribulations of other. 
This research also suggests that one become careless of other’s feelings. In two double-blind placebo-controlled 
experiments, participants perceived pain, personal distress and empathetic concerns in response to physical or 
social pain scenarios. As if hypnotized, acetaminophen reduced empathy in response to other’s pain. Because 
empathy regulates the pro-social and antisocial behavior, this drug-induced reduction in compassion has raised 
concern about broader social effects of acetaminophen, which is widely taken by patients on daily basis. 
Insulin  needle Length : Does it really matter? 
Khuban Arshad , Pharmacist, Ambulatory Care Pharmacy
Patients usually have apprehensions about the 4mm needles available in the AKUH pharmacies. Insulin is 
meant to be injected into the subcutaneous tissues and its thickness varies according to different sites ie arm, 
thigh, abdomen,etc. On average, thickness of human skin along with subcutaneous tissue is more than 2.8mm. 
Therefore, 4mm syringes can be safely used for insulin administration. Pharmacist can play a significant role in 
helping patients overcome their fear of injecting too deep.  Pharmacists should 
also counsel patients about selecting injection sites according to body weight/ 
BMI as mentioned in Figure 01. For example, choosing buttocks as the site of 
administration for abdominally obese patients can go a long way  promoting 
insulin acceptance and adherence. 
Immunization against Pneumococcal
Amna Mujeeb , Pharmacist, Inpatient Pharmacy
Two types of pneumococcal vaccinations for adults are available at AKUH pharmacy ie PCV13 & PPSV 
23. The former provides coverage against 13 strains and latter against 23 strains causing pneumonia. The 
important consideration in pneumococcal vaccination is the order & timing interval. Since, these two types of 
immunizations stimulate the immune system in different ways; therefore, the timing & order of administration 
are very important. Immune response is faster if PCV 13 is given first. Interval between PPSV23 & PCV 13 
depends upon age Group, medical condition, last administered vaccine, high risk group. 
Interval Recommendation:
 PSV23 1 year Interval PCV 13
 PPSV23 5 year Interval PPPSV23
 PCV 13 Age Medical Condition PPSV23
Figure 01
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Targeting the Low Anticoagulation Therapy in Valve Replacement
Fahmeen Kinza, Trainee Pharmacist
Anticoagulation regimens vary according to practice of surgeon, nature of the valve (mechanical or biological), 
position of valve and prevention of other risk factors including stroke etc.  INR recommendations of the The 
American College of Chest Physicians (ACCP) 2016   in various conditions ie mechanical valve in the aortic 
position, mitral position (MVR), Atrial Fibrillation and Prosthetic Valve Replacement are given in Table 01. 
Furthermore, several studies have shown the effectiveness of low target INR, when anticoagulant is used in 
combination with low dose aspirin, to significantly lower the risk of bleeding and thromboembolism.  Tables 01 
summarizes the ACCP recommendations and mean range of low INR therapy of several studies.
Mitral Valve Replacement (MVR)
Atrial Valve  Replacement  (AVR)
Atrial Fibrillation
Prosthetic Valve Replacement
2.5-3.5
2.0-3.5
2.0-3.0
3.0-4.5
1.8-3.0
1.3-2.5
1.5-2.1
2.0-3.0
Condition INR – ACCP Guideline Low INR Levels ( Studies Based)
*** In April 2015 FDA approved the On-X aortic heart valve with INR 1.5–2.0 following 3 months of standard anticoagulation therapy based on 
the successful completion of the AVR high risk arm of the PROACT study
Table 01:
Immuno-compromised
Asplenic
High-Risk immunocompetent
Cochlear implants
HIV but receive one dose 
PPSV23 one year ago
Asthma
Asthma + long term 
systemic corticosteroids
Geriatric with no vaccine history
Geriatric with PPSV23
19yrs – 64yrs
65yrs & older
65yrs & older
PCV13 8 WEEKS INTERVAL  1st dose PPSV23 
5 YEARS INTERVAL  2nd dose PPSV23
PCV13 8 WEEKS INTERVAL  1st dose 
PPSV232ND DOSE PPSV23 at age 65
give PCV13 stat2nd dose PPSV23 after 5 years 
interval of 1st dose PPSV23 3rd dose PPSV23 at age 
65 year
PPSV23  PCV13 at  age 65  1 year interval  2nd 
dose PPSV23
PCV13 stat 8 WEEKS INTERVAL  1st dose 
PPSV23 2ND DOSE PPSV23 at age 65
PCV13 1 year INTERVAL  PPSV23
Give PCV13 considering 1 year interval from last 
received PPSV23 
Medical Condition Age Group Vaccination Protocol
Recommended Interval:
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Fluoroquinolones,
Antibiotics
Aripiprazole,
Antipsychotic
Olanzapine,
Antipsychotic
Fluconazole,
Antifungal
Ketoconazole,
Antifungal
Systemic use is associated with the serious side 
effects including tendon, joint and muscle pain,” 
tingling or pricking sensation, confusion, and hal-
lucinations.
Uncontrollable urges to gamble, binge eat, shop, 
and have sex have been reported.
Drug Reaction with Eosinophilia and Systemic 
Symptoms (DRESS), a rare but serious skin 
reaction, has been reported with its use.  
A Danish Study showed increased risk of 
miscarriage with use of oral fluconazole. 
High risk of serious liver damage and adrenal gland 
problems with oral fluconazole
Restricting its use for certain uncompli-
cated infections where other treatment 
options are not available.  
Aware patient about the risk of these 
uncontrollable urges and specifically
ask about any new or increasing urges 
Explain signs and symptoms. Advise 
patients to seek immediate 
medical care if DRESS is suspected. 
Advise precaution
Suggest other agents  to treat skin and 
nail fungal infections
Drug of Concern Warning Recommendations
FDA Warnings 2016
Abdul Rauf- Pharmacist, Ambulatory Care Pharmacy
Time Saving Facilities for Employees at AKUH
Durr-e-Shahwar Siddiqui , Pharmacist, Ambulatory Care Pharmacy
Aga Khan University Hospital is well-known worldwide for providing excellent healthcare services to its cus-
tomers. We highly value our external as well as internal customers. For the accomplishment of our objective in 
rendering a better framework of pharmacy services at AKUH, we remain indulged in expanding the quality of 
pharmaceutical care. Following are the time-saving pharmacy facilities for AKUH staff, 
“PHAMED” For Doctors
A request e-mail can be sent by doctor at phamed@aku.edu for any required formulary 
medicine along-with the needed quantity, name & employee number. The requested 
order is then processed by the pharmacist & the employee is informed by a confirmatory 
e-mail after which the order can be collected by Nazar Ali Walji Pharmacy (Ext: 5702). 
This facility can be used for both prescription and over the counter medicines.
E-Pharmacy for All AKUH Employees
AKUH employee can place the order for available over-the-counter (OTC) medicines 
at website ie http://intranet/epharmacy . The processed order can by collected from 
Community Health Centre Pharmacy (Ext: 1512) after an approval e-mail is sent to 
employee stating that is/her order has completed. 
The above mentioned pharmacy facilities can surely save the time of our respected internal customers of 
AKUH which they spend in the queues of pharmacy. The saved time can be utilized for benefiting the patients. 
Hopefully the satisfaction levels of both the internal & external customers will be raised by such advantageous 
pharmaceutical services of AKUH. 
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The Aga Khan University Hospital, Karachi
Provide us your Valuable Feedback!
LINK: https://docs.google.com/forms/d/1IAduMbPm_X9yP9lN-OvpdYEEQLWFycho4U6uQWXet3c/edit# 
the feedback form can be emailed to you as well. Just drops us an email with the Subject Newsletter Feedback
Email us at: drug.information@aku.edu
Ask Away!
You may get an experts opinion by consulting with one of our specialist. Send in your questions at 
drug.information@aku.edu
Loperamide,
Antidiarrheal
Opioids
Analgesics
Serious heart problems that can lead to death. 
May cause adrenal insufficiency, serotonin syndrome 
(if used in combination with antidepressant or 
migraine medications) and long term use may result 
in decreased sex hormone levels and symptoms (low 
interest in sex, impotence, or infertility)
Follow the label’s dosing 
recommendations 
Discontinue treatment in case of 
serotonin syndrome and perform 
diagnostic testing if adrenal 
insufficiency is suspected.
Drug of Concern Warning Recommendations
WHO defines adverse drugs reaction as:
 “A response to a drug which is noxious, unintended, and which occurs at doses 
normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for 
the modifications of physiological function.”
Why Report?
	 P For continuous monitoring for ADR trends at AKUH
	 P To develop strategies for prevention of any complications
	 P To assess the quality of pharmaceutical care
	 P To evaluate safety of drug therapies, especially recently approved drugs
	 P To reduce the hospitalization of patient and minimize liability of our hospital
How to Report?
1. Call ADR Hotline- Ext 1477 ( 34861477)
2. Report Online : http://intranet/pharmacy/adrrf.htm
3. Fill out  “ Yellow Cards”
Take Action and Report an
Adverse Drug Reaction!
